Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy

Previous trial results showed signficant improvements in radiographic PFS and OS from adding apalutamide to ADT. The FDA recently approved the drug for metastatic castration-sensitive prostate cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news